

DiD2025 Summit Handout

General Information

- Doing it in the Desert: Viral Hepatitis & STI Elimination Summit 2025
- October 4, 2025, Phoenix, AZ
- Jointly provided by Postgraduate Institute for Medicine and Arizona Liver Health and elm Planning
- If applicable: This activity is supported by an independent educational grant from- N/A

Target Audience

 This activity is intended for physicians, PA's, Registered Nurses, Nurse Practitioners/APRN's, Pharmacists, Pharmacy Technicians, Residents, Fellows, and Social Workers engaged in the care of patients with Viral Hepatitis and STI Prevention & Treatment.

Educational Objectives

After completing this activity, the participant should be better able to:

- Gain the latest insights on operational and treatment strategies for HCV elimination.
- Gain the latest insights on operational and treatment strategies for HIV & STI prevention.
- Explore how research and development outcomes can shape evidence-based policymaking for STI care and elimination.
- Share knowledge and practical experiences in the clinical management of viral hepatitis including patient screening, engagement and management of medication adherence and safety
- Engage in cross-disciplinary discussions to address challenges in viral hepatitis elimination including diagnosis and management of co-morbid addiction and psychiatric disease
- Explore actionable steps to integrate research into policy and practice for STI care and elimination.
- Explore the role of new long-acting agents for HIV prevention

Faculty

- Lisa Barrett, MD, PhD, FRCPC
 - Assistant Professor, Clinical Investigator, Dalhousie University, Halifax Canada
- Sherilyn Brinkley, NPN
 - Nurse Practitioner Manager, Program Manager Clinical Services and Research Johns Hopkins University School of Medicine
- Elijah A. Byjoe, BIPH



- Senior Health Educator, Navajo Health Program
 Navajo Nation Department of Health, Tuba City Service Unit
- Cheryl Cook
 - O HIV Prevention Specialist, Navajo Health Education Program Navajo Nation Department of Health
- Paulina Deming, PharmD, PhC
 - O Director, Viral Hepatitis Programs- ECHO Institute
 - Associate Professor College of Pharmacy
 - University of New Mexico Health Sciences Center
- Gavin Ferguson, PA
 - Physician Assistant
 - o VEN Centers
- Anita Kohli, MD
 - CEO, Chief Research Officer
 Arizona Liver Health, VEN Centers, Arizona Clinical Trials
- Sequan Kolibas
 - Founder & Executive Director of Hope on T.T.a.P.P (Testing, Treatment, and Peer-led Prevention)
- Richard Manch, MD, MS, FAASLD, FACP, FACG
 - Senior Hepatologist, Arizona Liver Health
 - Medical Director, VEN Centers
- Ann Moore, NP
 - Nurse Practitioner
 Arizona Liver Health, VEN Centers
- Dylan Moore, RN
 - Director of VEN Centers
 VEN Centers, Arizona Liver Health
- Tony Martinez, MD
 - Associate Professor Medicine University of Buffalo
 - Medical Director Hepatology Erie County Medical Center
- John Ward, MD
 - O Director, Coalition for Global Hepatitis Elimination, Task Force for Global Health
 - Professor in the Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly mitigated according to PIM policy. PIM is



committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:

- Lisa Barrett, MD, PhD, FRCPC
 Consultant/Advisory Board with Gilead, MBS, Pfizer (all advisory work)
- Sherilyn Brinkley, NPN
 Speakers Bureau with Gilead Sciences, Abbvie
- Elijah A. Byjoe, BIPH
 Elijah A. Byjoe has nothing to disclose.
- Cheryl Cook
 Cheryl Cook has nothing to disclose.
- Paulina Deming, PharmD, PhC
 Paulina Deming, has nothing to disclose.
- Gavin Ferguson, PA
 Speakers Bureau: ALH/VEN Center speaker at DiD Conference 2024. Relationship ended due to full time employment with VEN Centers in August of 2024. Consultant/Advisory Board with Gilead
- Anita Kohli, MD

<u>Grant/Research Support</u> from 89Bio, AbbVie, Aligos, Altimmune, Amgen, Akero, AstraZeneka, Genentech, Axcella, Bavarian Nordic, Boehringer Ingelheim, Bristol-Myers, Boston Pharmaceuticals, Corcept, Cymabay, Eli Lilly, Galectin, GSK, Gilead, Hepagene, Hepion, Intercept, Inventiva, Ionis, Ipsen, Madrigal, Merck, NGM, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Regeneron, Salix, Terns, Takeda, Viking, VIR, and Zydus.

Speakers Bureau with Gilead

<u>Consultant/Advisory Board</u> with Madrigal, Gilead, Boehringer Ingelheim, Ipsen, Iqirvo, Iqvia

Sequan Kolibas
 Speakers/Bureau with Gilead Sciences



Consultant/Advisory Board with Abbvie

- Richard Manch, MD, MS, FAASLD, FACP, FACG
 <u>Grant/Research Support</u> with Merck, 89 Bio, AKERO, SALIX, Viking, Atea
 <u>Speakers Bureau</u> with Gilead, AbbVie, Intercept, Madrigal
 <u>Consultant/Advisory Board</u> with Ipsen, Gilead, Intercept
- Ann Moore, NP
 <u>Grant/Research Support</u> from Gilead, Atea, Novo
 <u>Speakers Bureau</u> with Abbvie, Gilead, Ipsen, Intercept
 <u>Consultant/Advisory Board</u> with Abbvie, Gilead, Ipsen, Intercept, Novo, GSK, Seimans
- Dylan Moore, RN
 Speakers Bureau with Abbvie
 Consultant/Advisory Board with Gilead
- Tony Martinez, MD
 <u>Grant/Research</u> with Cepheid
 <u>Speakers Bureau</u> with Gilead, Abbvie, Braeburn, Madrigal, Ipsen
 <u>Consultant/Advisory Board</u> with Gilead, Abbvie, Madrigal, Ipsen, Cepheid, Roche, Arbutus, Altimmune, Atea
- John Ward, MD
 <u>Grant/Research</u> funding: The Task Force for Global Health receives funds for the general support of the Coalition for Global Hepatitis Elimination from: Abbott, AbbVie, Gilead Sciences, Merck, Pharco, Roche, Siemens, Virion, and Zydus Lifesciences.
 Speakers Bureau with Abbott, Gilead, Roche, Siemens

The PIM planners and others have nothing to disclose. The elm Planning, Arizona Liver Health planners and others have nothing to disclose

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, Arizona Liver Health and elmPlanning. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the

American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 6.25 *AMA PRA Category 1 Credit*(s) $^{\text{TM}}$. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 6.25 contact hours.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 6.25 contact hour(s) (0.625 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number JA4008162-9999-25-577-L01-P Type of Activity: Knowledge

Hardware/Software Requirements (Required for Internet-based ACPE activities only)

Include minimum hardware, software, internet connectivity and connection speed requirements for accessing the internet-based activity.

Policy on Privacy and Confidentiality (Required for Internet-based ACPE activities only)

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Continuing Physician Assistant Education



Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Continuing Social Work Education

As a Jointly Accredited Organization, Postgraduate Institute for Medicine is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Postgraduate





Institute for Medicine maintains responsibility for this course. Social workers completing this course receive 6.25 Community Health continuing education credits.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.